Clinical Scorecard: Several motor proteins control anterograde axonal transport of TDP-43
At a Glance
Category
Detail
Condition
Axonal transport of TDP-43, an RNA-binding protein implicated in several neurodegenerative diseases
Key Mechanisms
TDP-43-containing ribonucleoprotein complexes move along axons; the study reports interactions with kinesin-1 isoforms KIF5A, KIF5B, and KIF5C via KLC1, and with kinesin-3 KIF1A.
Target Population
Human neurons derived from the H9 embryonic stem-cell line under physiological conditions
Care Setting
Preclinical cell-based research using live-cell imaging, biochemical assays, and proximity ligation analyses
Key Highlights
Live-cell imaging showed processive anterograde movement of TDP-43 in H9-derived neurons, with kinetics comparable to vesicular cargoes.
TDP-43 interacted with all three kinesin-1 isoforms—KIF5A, KIF5B, and KIF5C—via KLC1.
TDP-43 also interacted with KIF1A, a kinesin-3 family member.
Biochemical and proximity ligation analyses found interactions with anterograde and retrograde transport machinery, consistent with bidirectional transport.
The authors propose that TDP-43-containing complexes may use a flexible multi-motor transport system; the contribution of transport disruption to ALS pathology remains uncertain.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
The article describes TDP-43 pathology in ALS, FTLD-TDP-43, and LATE, among other neurodegenerative disorders.
In approximately 97% of sporadic ALS cases, the source reports nuclear TDP-43 depletion together with aberrant cytoplasmic accumulation.
The article states that nuclear TDP-43 loss can cause cryptic exon splicing in STMN2 and UNC13A transcripts, while cytoplasmic accumulation can disrupt mRNA transport and local translation.
Patient & Prescribing Data
No patient cohort or prescribing population was studied; experiments used H9-derived human neurons.
No treatment or prescribing recommendations are reported.
Clinical Best Practices
Interpret the findings as preclinical evidence from H9-derived neurons, not as clinical guidance.
The article identifies the contribution of disrupted TDP-43 transport to ALS pathology as unresolved.
by Monica Feole, Victorio M. Pozo Devoto, Neda Dragišić, Maria Čarna, Katja Klosterman, Clara Limbaek-Stokin, Giancarlo Forte, Kenneth L. Moya, Richard A. Smith, Clive N. Svendsen, Gorazd B. Stokin
